On the Record · Sarepta Therapeutics
Sarepta Therapeutics acquisitions, on the record
The businesses Sarepta Therapeutics bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Myonexus Therapeutics Inc.Word for word“In April 2019, we acquired Myonexus Therapeutics Inc. ("Myonexus"), a privately-held Delaware corporation, for $173.8 million pursuant to an exclusive warrant to purchase Myonexus that we purchased in May 2018 for an up-front payment of $60.0 million.” 10-K for 2023 | acquisition | April 2019 | $173.8 million |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) |
|---|---|
| 2019-12-31 | $172.6 million |
Deal filings since 2016
- 2026-09-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-12-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-08-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-02-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-11-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-03-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-09-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-10-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-09-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-12-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-12-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-03-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-02-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-11-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-11-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-07-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-07-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-07-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-03-31 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2017-02-21 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-10-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-09-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-06-10 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Sarepta Therapeutics’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-03-02. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.